Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

导出原文传递

翻译打印收藏纠错

作者： Cella, David ^[1] ; Gruenwald, Viktor ^[2] ; Escudier, Bernard ^[3] ; Hammers, Hans J. ^[4] ; George, Saby ^[5] ; Nathan, Paul ^[6] ; Grimm, Marc-Oliver ^[7] ; Rini, Brian, I ^[8] ; Doan, Justin ^[9] ; Ivanescu, Cristina ^[10] ; Paty, Jean ^[11] ; Mekan, Sabeen ; Motzer, Robert J.

作者单位： IQVIA, Durham, NC USA ^[1] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA ^[2] UT Southwestern, Dallas, TX USA ^[3] Hannover Med Sch, Hannover, Lower Saxony, Germany ^[4] Bristol Myers Squibb, Princeton, NJ USA ^[5] Northwestern Univ, Chicago, IL 60611 USA ^[6] Inst Gustave Roussy, Villejuif, France ^[7] Mt Vernon Canc Ctr, London, England ^[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA ^[9] Roswell Pk Canc Inst, Buffalo, NY USA ^[10] Jena Univ Hosp, Dept Urol, Jena, Germany ^[11]

发布时间 2019-09-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

The lancet oncology

2019年20卷2期

297-310页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

The lancet oncology

相似文献

The lancet oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

The lancet oncology

相似文献

The lancet oncology

相关期刊

检索历史清除